Home Biosimilar Antibodies Others Others Anti-ANGPT2 (MEDI3617)
For research use only. Not for use in humans.

Anti-ANGPT2 (MEDI3617)

Synonyms: ANG-2， angiopoietin 2

Anti-ANGPT2 (MEDI3617) is a human IgG1 kappa monoclonal antibody directed against the angiogenic cytokines angiopoietin-2 (Angpt2). MEDI3617 in combination with tremelimumab is used to treat advanced melanoma. MW: 145.82 kD.

Anti-ANGPT2 (MEDI3617)

Quality Control

Batch: A277001 Purity: 99% Protein concentration: 13mg/ml Endotoxin Level: ＜1EU/mg
99

Mechanism of Action

Description
Anti-ANGPT2 (MEDI3617) is a human IgG1 kappa monoclonal antibody directed against the angiogenic cytokines angiopoietin-2 (Angpt2). MEDI3617 in combination with tremelimumab is used to treat advanced melanoma. MW: 145.82 kD.
References

Product Details

Molecular Weight 145.82
Isotype Human IgG2SA
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02141542 COMPLETED Drug: Tremelimumab|Drug: MEDI3617 Metastatic Melanoma F. Stephen Hodi, MD 2014-05 PHASE1
NCT01248949 COMPLETED Drug: MEDI3617|Drug: Bevacizumab|Drug: Paclitaxel|Drug: Carb Advanced Solid Tumors; Advanced Recurrent Ovarian Tumors MedImmune LLC 2010-10 PHASE1

(data from https://clinicaltrials.gov, updated on 2023-05-01)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.